Sanofi and Regeneron ’s two Phase IIIb/IV trials of alirocumab meet primary endpoint

Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase IIIb/IV DM-INSULIN and DM-DYSLIPIDEMIA clinical trials of Praluent (alirocumab) to treat patients with diabetes and hypercholesterolemia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news